TP53 and non-small cell lung carcinoma: Here, we evaluated the therapeutic response of volasertib in the NSCLC cell lines A549 (p53 wild‐type) and its isogenic derivatives A549‐NTC (nontemplate control, p53 wild‐type) and A549‐920 (p53 shRNA knockdown), as well as in the TP53 mutant NCI‐H1975 cell line (R273H).